Australia-listed stem cell biotech Mesoblast prices IPO at $8, below expectations

Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq. J.P. Morgan and Credit Suisse acted as lead managers on the deal.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.